According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Aurobindo has one of the most enduring generics ecosystems among peers
The company plans to enter the EU markets in FY22
The company is working closely with its six manufacturing partners in India
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Subscribe To Our Newsletter & Stay Updated
